4GS8 image
Entry Detail
PDB ID:
4GS8
Title:
Structure analysis of cysteine free insulin degrading enzyme (ide) with compound bdm43079 [{[(s)-2-(1h-imidazol-4-yl)-1-methylcarbamoyl-ethylcarbamoyl]-methyl}-(3-phenyl-propyl)-amino]-acetic acid
Biological Source:
Source Organism:
Host Organism:
PDB Version:
Deposition Date:
2012-08-27
Release Date:
2013-08-28
Method Details:
Experimental Method:
Resolution:
2.99 Å
R-Value Free:
0.23
R-Value Work:
0.17
R-Value Observed:
0.18
Space Group:
P 65
Macromolecular Entities
Polymer Type:polypeptide(L)
Description:Insulin-degrading enzyme
Mutations:C110L,E111Q,C171S,C178A,C257V,C414L,C573N,C590S,C789SC812A,C819A,C904S,C966N,C974A
Chain IDs:A, B
Chain Length:990
Number of Molecules:2
Biological Source:Homo sapiens
Primary Citation
Imidazole-derived 2-[N-carbamoylmethyl-alkylamino]acetic acids, substrate-dependent modulators of insulin-degrading enzyme in amyloid-beta hydrolysis.
Eur.J.Med.Chem. 79 184 193 (2014)
PMID: 24735644 DOI: 10.1016/j.ejmech.2014.04.009

Abstact

Insulin degrading enzyme (IDE) is a highly conserved zinc metalloprotease that is involved in the clearance of various physiologically peptides like amyloid-beta and insulin. This enzyme has been involved in the physiopathology of diabetes and Alzheimer's disease. We describe here a series of small molecules discovered by screening. Co-crystallization of the compounds with IDE revealed a binding both at the permanent exosite and at the discontinuous, conformational catalytic site. Preliminary structure-activity relationships are described. Selective inhibition of amyloid-beta degradation over insulin hydrolysis was possible. Neuroblastoma cells treated with the optimized compound display a dose-dependent increase in amyloid-beta levels.

Legend

Protein

Chemical

Disease

Primary Citation of related structures